Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone to Block SGLT2i-induced Effects in T1D
NCT07056699Phase 3Recruiting
- Sponsor
- UT Health San Antonio
- Start
- Jul 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of pioglitazone in type 1 diabetes mellitus (T1D) (2 arms), sponsored by UT Health San Antonio. Primary endpoints: Endogenous glucose production at Week 16, Ketone body production at Week 16 and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
pioglitazone
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT07056699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07056699.